Stimcell Energetics INC
Market Movers (8-K)
OQB
StimCell Energetics Inc. announced a new research collaboration to study its eBalance device's impact on neuronal mitochondrial function.
OQB
StimCell Energetics announces debt settlement via share issuance, a strategic partnership with Rain Communications for investor relations, and provides an update on the eBalance microcurrent therapy device redesign.
OQB
8-K: StimCell Energetics Partners with ADM Tronics to Redesign eBalance Microcurrent Device for Home Use
StimCell Energetics collaborates with ADM Tronics to create a smaller, more affordable eBalance microcurrent device for home use with advanced diagnostic features.
OQB
StimCell Energetics Inc. has partnered with Think Ink Marketing to enhance public awareness of the company and its products through a six-month marketing agreement.
OQB
StimCell Energetics Inc., formerly Cell MedX Corp., has completed a 1-for-15 reverse stock split and rebranded, aiming to redefine its strategic vision in cellular energetics.
OQB
Cell MedX Corp. has appointed new directors and increased its authorized share capital to 7.5 billion shares, effective April 1, 2024.
Capital raise
Quarterly Earnings (10-Q)
OQB
Stimcell Energetics Inc. reported a wider net loss for the nine months ended February 28, 2026, driven by increased research and development costs for its eBalance device redesign, alongside significant related party transactions.
Capital raise
Worse than expected
OQB
Stimcell Energetics Inc. reported a significant increase in net loss and a worsening working capital deficit for the six months ended November 30, 2025, raising substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
Delay expected
OQB
Stimcell Energetics Inc. reported a significantly increased net loss and a worsening working capital deficit for Q1 2026, raising substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
OQB
Stimcell Energetics Inc. reports increased operating expenses and a net loss for Q3 2025, alongside ongoing concerns about its ability to continue as a going concern.
Capital raise
Worse than expected
OQB
Stimcell Energetics Inc. reports a significant increase in operating expenses and net loss for the second quarter of fiscal year 2025, alongside a reverse stock split and name change.
Worse than expected
Capital raise
OQB
10-Q: Cell MedX Corp. Reports Q1 2025 Results: Operating Expenses Rise Amidst Ongoing Financial Challenges
Cell MedX Corp.'s Q1 2025 report reveals increased operating expenses and a continued net loss, highlighting the company's ongoing financial challenges.
Worse than expected
Capital raise
Annual Reports (10-K)
OQB
Stimcell Energetics Inc. reported a significant increase in net loss for fiscal year 2025, alongside a restart of eBalance device redesign and ongoing reliance on related-party financing.
Delay expected
Capital raise
Worse than expected
OQB
10-K: Cell MedX Corp. Reports Fiscal Year 2024 Results Amidst Financial Challenges and Strategic Shift
Cell MedX Corp.'s annual report reveals a year of financial difficulties, including suspended operations and a significant debt conversion, alongside a strategic shift away from active research and development.
Capital raise
Worse than expected
Insider Trading (Form 4)
OQB
Amir Vahabzadeh, a Director and 10% owner of Stimcell Energetics Inc., reported selling 16,667 common shares at $0.34 per share.
Worse than expected
OQB
Form 4: Stimcell Energetics Director Amir Vahabzadeh Reports Share Acquisition and Reverse Stock Split
Director Amir Vahabzadeh reports acquisition of shares and impact of a reverse stock split on beneficial ownership of Stimcell Energetics Inc.
OQB
Richard Jeffs, a director and 10% owner of Stimcell Energetics Inc., reports the acquisition of common shares and adjustments due to a reverse stock split.
Proxy Statements (Def-14A)
OQB
DEF 14C: CellMedX Corp. Proposes Increase in Authorized Capital and Director Elections via Written Consent
CellMedX Corp. announces plans to increase its authorized capital from 300 million to 7.5 billion shares and elect four directors through written consent of majority shareholders.
Capital raise